On April 15, 2016 Lytix Biopharma reported that Lytix Biopharma presented 4 posters at AACR (Free AACR Whitepaper) in New Oreleans April 2016 (Press release, Lytix Biopharma, APR 15, 2016, View Source [SID:1234514845]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Andrew Saunders (CMO), Øystein Rekdal (CSO), Baldur Sveinbjørnsson (Senior researcher), Ketil Camilio (Senior researcher) and Brynjar Mauseth (PhD Student) represented Lytix Biopharma at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) in New Orleans April 16-21, 2016. Leading scientists and a large number of pharmaceutical companies attends the conference, and the mission is to prevent and cure cancer through research, education, communication and collaboration.
Together with scientific collaborators at Institut Gustav Roussy, Oslo University Hospital and University of Tromsø Lytix Biopharma presented 4 posters at the conference:
Sunday April 17, 2016:
Enhanced antitumor activity achieved by combining the oncolytic peptide LTX-315 with anti-PD-L1 antibody
Monday April 18, 2016:
LTX-315, an oncolytic peptide, increases anticancer immunity mediated by CTLA4 blockade in an interleukin-2 receptor beta-chain-dependent manner
The amphiphatic ß(2,2)-amino acid LTX-401 induces complete regression of experimental hepatocellular carcinoma
Wednesday April 20, 2016:
The oncolytic peptide LTX-315 enhances tumor-specific immune responses and tumor regression in murine 4T1 breast cancer when combined with doxorubicin